Dianthus Therapeutics Files 8-K

TL;DR

Dianthus Therapeutics filed an 8-K. Routine update.

AI Summary

Dianthus Therapeutics, Inc. filed an 8-K on December 12, 2024, to report other events and financial statements. The company, formerly known as Magenta Therapeutics, Inc., is incorporated in Delaware and has its principal executive offices in New York City.

Why It Matters

This filing indicates routine corporate reporting by Dianthus Therapeutics, Inc., providing updates on its operational and financial status to the SEC.

Risk Assessment

Risk Level: low — This is a standard SEC filing for corporate reporting and does not appear to contain significant new information that would immediately impact risk.

Key Numbers

• 001-38541 — SEC File Number (Identifies the company's filing with the SEC.)
• 81-0724163 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• Dianthus Therapeutics, Inc. (company) — Registrant
• Magenta Therapeutics, Inc. (company) — Former Name
• December 12, 2024 (date) — Date of Report
• New York (location) — Principal Executive Offices City
• Delaware (location) — State of Incorporation

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 Par Value DNTH The Nasdaq Capital M

Filing Documents

• dnth-20241212.htm (8-K) — 45KB
• dnth-ex99_1.htm (EX-99.1) — 36KB
• dnth-ex99_1s1.jpg (GRAPHIC) — 404KB
• dnth-ex99_1s2.jpg (GRAPHIC) — 545KB
• dnth-ex99_1s3.jpg (GRAPHIC) — 445KB
• dnth-ex99_1s4.jpg (GRAPHIC) — 493KB
• dnth-ex99_1s5.jpg (GRAPHIC) — 389KB
• dnth-ex99_1s6.jpg (GRAPHIC) — 427KB
• dnth-ex99_1s7.jpg (GRAPHIC) — 491KB
• dnth-ex99_1s8.jpg (GRAPHIC) — 420KB
• dnth-ex99_1s9.jpg (GRAPHIC) — 455KB
• dnth-ex99_1s10.jpg (GRAPHIC) — 376KB
• dnth-ex99_1s11.jpg (GRAPHIC) — 137KB
• dnth-ex99_1s12.jpg (GRAPHIC) — 453KB
• dnth-ex99_1s13.jpg (GRAPHIC) — 399KB
• dnth-ex99_1s14.jpg (GRAPHIC) — 430KB
• dnth-ex99_1s15.jpg (GRAPHIC) — 347KB
• dnth-ex99_1s16.jpg (GRAPHIC) — 126KB
• dnth-ex99_1s17.jpg (GRAPHIC) — 308KB
• dnth-ex99_1s18.jpg (GRAPHIC) — 346KB
• dnth-ex99_1s19.jpg (GRAPHIC) — 317KB
• dnth-ex99_1s20.jpg (GRAPHIC) — 451KB
• dnth-ex99_1s21.jpg (GRAPHIC) — 376KB
• dnth-ex99_1s22.jpg (GRAPHIC) — 389KB
• dnth-ex99_1s23.jpg (GRAPHIC) — 457KB
• dnth-ex99_1s24.jpg (GRAPHIC) — 108KB
• dnth-ex99_1s25.jpg (GRAPHIC) — 439KB
• dnth-ex99_1s26.jpg (GRAPHIC) — 480KB
• dnth-ex99_1s27.jpg (GRAPHIC) — 108KB
• dnth-ex99_1s28.jpg (GRAPHIC) — 334KB
• dnth-ex99_1s29.jpg (GRAPHIC) — 394KB
• dnth-ex99_1s30.jpg (GRAPHIC) — 610KB
• dnth-ex99_1s31.jpg (GRAPHIC) — 353KB
• 0000950170-24-135775.txt ( ) — 16498KB
• dnth-20241212.xsd (EX-101.SCH) — 56KB
• dnth-20241212_htm.xml (XML) — 5KB

01 Other Events

Item 8.01 Other Events. On December 12, 2024, Dianthus Therapeutics, Inc. posted an updated corporate presentation (the "Presentation") on the investor relations section of its website. The Presentation is filed as Exhibit 99.1 and is incorporated by reference into this Item 8.01. Cautionary Note Regarding Forward-Looking Statements. The Presentation contains forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ materially from those expressed or implied by these statements. Please refer to the cautionary notes in the Presentation regarding these forward-looking statements.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Corporate Presentation of Dianthus Therapeutics, Inc., dated December 2024 104 Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DIANTHUS THERAPEUTICS, INC. Date: December 12, 2024 By: /s/ Adam M. Veness, Esq. Adam M. Veness, Esq. SVP, General Counsel and Secretary

View Full Filing

View this 8-K filing on SEC EDGAR